irinotecan has been researched along with trichostatin a in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artali, R; Bianchino, E; Cardile, F; Cincinelli, R; Colelli, F; Dallavalle, S; Guglielmi, M; Musso, L; Pisano, C | 1 |
| Bernshausen, A; Bieler, A; Dravits, T; Gansbacher, B; Glockzin, G; Holm, PS; Köhler-Vargas, N; Lage, H; Mantwill, K | 1 |
| Bernard, O; Gagnon, JF; Guillemette, C; Têtu, B; Villeneuve, L | 1 |
| Costanzo, C; Donadelli, M; Moore, PS; Palmieri, M; Piacentini, P; Scarpa, A | 1 |
| Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
5 other study(ies) available for irinotecan and trichostatin a
| Article | Year |
|---|---|
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; Disulfides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tyrosine | 2018 |
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Blotting, Southern; Brain Neoplasms; Camptothecin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Enzyme Inhibitors; Fibroblasts; Gene Deletion; Gene Expression; Gentian Violet; Glioblastoma; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Irinotecan; Oncolytic Viruses; Protein Synthesis Inhibitors; Receptors, Virus; Tumor Cells, Cultured | 2006 |
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
Topics: Azacitidine; Camptothecin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronides; Glucuronosyltransferase; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan | 2006 |
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Irinotecan; Pancreatic Neoplasms; Protein Synthesis Inhibitors | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |